Addition Of Platinum Research Articles

Physically and chemically modified zeolite templated nitrogenous carbons for enhanced hydrogen adsorption

Carbon materials have great potential for hydrogen adsorption due to their remarkable specific surface area, unique pore size characteristics and ability to functionalize with metal or non-metal. In this work, zeolite templated carbons were physically and chemically modified by varying preparation conditions to study their impact on structure and hydrogen adsorption capacity. The resultant templated carbons showed surface area in the range of 608–1665 m2/g and pore volume between 0.63 to 1.00 cc/g, with 28–48 % microporosity depending on synthesis conditions. The surface area and pore volume increased with increasing carbon deposition temperature from 650 to 750 °C and both decreased at higher carbon deposition temperature of 850 °C. At heat treatment temperature of 900 °C, the surface area and pore volume of templated carbons were observed to be higher. Incorporation of nitrogen heteroatom in carbon matrix during carbon deposition might have facilitated porosity. Use of argon as carrier gas resulted in the highest surface area (1665 m2/g), micropore area (597 m2/g) and pore volume (1.0 cc/g). The same templated carbon showed maximum hydrogen adsorption capacity of 0.20 and 2.81 wt% at 25 and –196 °C, respectively at 15 bar. On addition of platinum to templated carbon, the hydrogen adsorption capacity was significantly improved from 0.20 to 0.28 wt% at 25 °C and from 2.81 to 3.24 wt% at –196 °C. The strong affinity of Pt for hydrogen might have enhanced hydrogen adsorption.

The Influence of Pt Additives on The Activity and Stability of Rh-containing Catalyst Performance in Diesel Fuel Conversion into Syngas

The influence of platinum additives on the properties of rhodium catalysts in steam and autothermal reforming processes of diesel fuel was investigated. It was found that the Rh/CZF catalyst exhibited higher activity, with a higher degree of fuel conversion and lower production of side reaction products compared to the bimetallic Rh–Pt/CZF catalyst. The proposed two-zone catalytic Pt/CZF+Rh/CZF structured honeycomb catalyst demonstrated stable performance and high activity in autothermal reforming of commercial diesel fuel. However, the presence of platinum in the frontal zone of the catalyst reduced its resistance to coking compared to the rhodium-containing sample. The obtained results are of practical significance in the development of efficient systems for the conversion of heavy hydrocarbons into synthesis gas.

[Artículo traducido] Efectividad y seguridad del tratamiento neoadyuvante del cáncer de mama triple negativo en la vida real

ObjectiveTriple-negative breast cancer is a subtype of aggressive breast cancer. Our aim is to evaluate the effectiveness and safety of neoadjuvant treatment in early-stage triple-negative breast cancer and to identify predictors of pathological complete response. MethodsThis is a single-center, retrospective study involving 79 patients with triple-negative breast cancer who initiated neoadjuvant treatment between January 2017 and October 2022. Descriptive analyses were performed as appropriate. Statistical analysis utilized bivariate logistic regression to explore the presence of factors related to pathological complete response, and the Kaplan–Meier method was employed for survival analysis. ResultsIn the overall population, 27 patients (n = 78; 34.6%) achieved pathological complete response in the breast and axillary lymph nodes, and 31 (n = 73; 42.5%) achieved a grade 5 pathological complete response in the breast, according to the Miller and Payne classification. The addition of platinum to standard therapy improved both breast and axillary lymph node pathological complete response rates. Age less than 40 years was identified as a predictor of pathological complete response in our study population through bivariate analysis, while Ki67 levels lower than 70% were associated with a lower pathological complete response rate. Adverse events were reported in 72 patients (91.1%), with grade 3–5 adverse events observed in 33 (41.8%). There was a particularly notable increase in gastrointestinal and hematological adverse events when platinum was added. ConclusionsIn this population, we observed moderate rates of pathological complete response with acceptable chemotherapy tolerance. Platinum-based chemotherapy appears to enhance the likelihood of achieving pathological complete response, albeit with a less favorable safety profile. Therefore, evaluating the benefit–risk balance is crucial when selecting the optimal chemotherapy regimen for individual patients.

A comparison of Ni, Pt, and NiPt catalysts supported on SBA-15 in anisole hydrodeoxygenation: Exploring the effect of platinum addition to a nickel catalyst

AbstractNi, Pt, and NiPt catalysts supported on SBA-15 were synthesized, characterized, and tested in anisole hydrodeoxygenation to determine the effect of the metal’s nature on the catalytic activity in the hydrogenation of the aromatic ring of anisole and hydrogenolysis of the C–O bond in the cyclohexyl methyl ether intermediate. Metal loadings in the catalysts were 5 wt% of Ni and 1 wt% of Pt. The bimetallic NiPt/SBA-15 catalyst showed the highest catalytic activity in both hydrogenation and hydrogenolysis, attributed to the promotional effect of Pt on NiO reduction and the formation of a Ni–Pt alloy with better dispersion of metal nanoparticles. Graphical abstract

Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study

BackgroundPrevious studies have shown that the addition of platinum to neoadjuvant chemotherapy (NAC) improved outcomes for patients with triple-negative breast cancer (TNBC). However, no studies have assessed the efficacy and safety of the combination of taxane and lobaplatin. In this study, we conducted a randomized controlled phase II clinical study to compare the efficacy and safety of taxane combined with lobaplatin or anthracycline.MethodsWe randomly allocated patients with stage I–III TNBC into Arm A and Arm B. Arm A received six cycles of taxane combined with lobaplatin (TL). Arm B received six cycles of taxane combined with anthracycline and cyclophosphamide (TEC) or eight cycles of anthracycline combined with cyclophosphamide and sequential use of taxane (EC-T). Both Arms underwent surgery after NAC. The primary endpoint was the pathologic complete response (pCR). Secondary endpoints were event-free survival (EFS), overall survival (OS), and safety.ResultsA total of 103 patients (51 in Arm A and 52 in Arm B) were assessed. The pCR rate of Arm A was significantly higher than that of Arm B (41.2% vs. 21.2%, P = 0.028). Patients with positive lymph nodes and low neutrophil-to-lymphocyte ratio (NLR) benefited significantly more from Arm A than those with negative lymph nodes and high NLR (Pinteraction = 0.001, Pinteraction = 0.012, respectively). There was no significant difference in EFS (P = 0.895) or OS (P = 0.633) between the two arms. The prevalence of grade-3/4 anemia was higher in Arm A (P = 0.015), and the prevalence of grade-3/4 neutropenia was higher in Arm B (P = 0.044).ConclusionsNeoadjuvant taxane plus lobaplatin has shown better efficacy than taxane plus anthracycline, and both regimens have similar toxicity profiles. This trial may provide a reference for a better combination strategy of immunotherapy in NAC for TNBC in the future.

Effects of Metal Promoters (M = Fe, Co, and Cu) in Pt/M x Zr y O z Catalysts and Influence of CO2 and H2O on the CO Oxidation Activity (PROX): Analysis of Surface Properties After Reaction.

In the present paper, the effects of metal promoters (M = Fe, Co, and Cu) in Pt/M x Zr y O z catalysts and the influence of CO2 and H2O on the CO oxidation activity (PROX) were investigated. To do that, characterizations of catalyst structures and surfaces were performed and reported here. The catalyst Pt/Fe x Zr y O z (PFeZ) was the most active at low temperatures among the analyzed ones. The addition of platinum caused strong interaction with the mixed oxide, affecting the structure and the surface composition, blocking basic sites, and thus preventing catalyst deactivation. Particularly, diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS) results evidenced the formation of carboxylate and carbonate species. Besides, the addition of CO2 and H2O in the gas feed stream affected the observed CO oxidation results, showing that CO2 competes with O2 on metallic sites. Moreover, DRIFTS and temperature-programmed desorption (TPD) analyses suggested the occurrence of OH- oxidation by CO, leading to the formation of highly reactive compounds that can be easily oxidized.

Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).

591 Background: The current standard of care for stage II-III TNBC is neoadjuvant Tx combining carboplatin, paclitaxel, and immune checkpoint inhibitor (ICI) followed by doxorubicin and cyclophosphamide (AC) + ICI. This regimen is often associated with significant toxicity. This study aimed to investigate if HRDsig could identify patients with TNBC who have a greater benefit from the addition of platinum in the neoadjuvant Tx regimen. Methods: This study included patients with TNBC who underwent genomic testing using Foundation Medicine tissue comprehensive genomic profiling (CGP) assays and had records of neoadjuvant Tx. Patient clinical data was obtained by the US-wide de-identified Flatiron Health and Foundation Medicine real-world clinicogenomic breast cancer database (CGDB), originated from ~280 US cancer clinics between January 2011 and June 2023. pCR rates were compared between patients HRDsig(+) vs. HRDsig(-) who were stratified by having received platinum vs. non-platinum Tx and between patients receiving non-platinum vs. platinum neoadjuvant Tx stratified by HRDsig status. The interaction effect of HRDsig and platinum Tx in relation to pCR was evaluated by logistic regression. Results: 497 patients met the inclusion criteria, 159 (32%) with HRDsig(+) and 338 (68%) with HRDsig(-). Among HRDsig(+) patients, 54 (34%) received platinum and 105 (66%) non-platinum Tx. HRDsig(+) vs. HRDsig(-) patients were more likely to have pCR receiving both platinum Tx (37.0% vs. 4.4%, p<0.001) and non-platinum Tx (23.8% vs. 5.2%, p<0.001). Platinum vs. non-platinum Tx showed a trend towards moderately enriched pCR rates in the HRDsig(+) group (37.0% vs. 23.8%, odds ratio [OR]=1.87, 95% confidence interval [CI] 0.97-3.84, p=0.08), but not in the HRDsig(-) group (4.5% vs. 5.2%, OR=0.86, 95% CI 0.23-2.55, p=0.767). HRDsig(+) was independently associated with pCR (OR=5.65, 95% CI 2.80-11.89, p<0.001), while platinum Tx and pCR were not associated (OR=0.84, 95% CI 0.23-2.45, p=0.767). A strong treatment interaction between HRDsig status and platinum Tx was not observed (p=0.242, OR=2.24, 95% CI 0.61-9.58). Conclusions: In the neoadjuvant Tx setting, patients with TNBC that were HRDsig(+) were substantially more likely to achieve a pCR. There was a trend towards higher pCR rates among HRDsig(+) patients receiving platinum vs. non-platinum Tx, while this effect was not observed among HRDsig(-) patients. TNBC patients (especially stage II) often experience significant toxicity from chemotherapy regimens. These hypothesis-generating results suggest that HRDsig may help identify patients who achieve additional benefit from platinum agents. These results warrant further evaluation in randomized cohorts to potentially validate this utility.

Abstract PS16-06: Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study

Abstract Background Previous studies have presented compelling evidence suggesting that the inclusion of platinum agents alongside anthracyclines and taxanes could potentially enhance treatment outcomes in high-risk triple-negative breast cancer (TNBC). Moreover, pembrolizumab has been integrated into clinical practice as a part of standard-of-care for non-metastatic TNBC with high risk. In light of these findings, we undertook a real-world study to investigate the impact of incorporating platinum agents and pembrolizumab on achieving pathologic complete response (pCR) in TNBC patients undergoing neoadjuvant chemotherapy (NAC). Furthermore, we specifically examined the influence of tumor-infiltrating lymphocytes (TILs) on the treatment outcomes. Patients and Methods In this real-world study conducted at Gangnam Severance Hospital, Seoul, Republic of Korea, we analyzed a cohort of 398 patients with TNBC who underwent surgery following NAC between March 2007 and November 2022. Among them, 247 patients received an anthracycline-taxanes (A-T), 120 received a carboplatin regimen including A-T, and 31 received a pembrolizumab regimen including A-T-carboplatin as part of their neoadjuvant chemotherapy treatment. TIL was evaluated in biopsied samples prior to NAC according to the guideline of TIL international working group. The high TIL was defined with a cutoff of 50%. Results Among the 398 patients analyzed, 87 (21.9%) had high TIL tumors. The pCR rates were 32% in the anthracycline-taxane (A-T) regimen group, 57% in the A-T-carboplatin regimen group, and 68% in the pembrolizumab with A-T-carboplatin regimen group. Within the high TIL group, the pCR rate did not increase with the addition of carboplatin (51.8% in the A-T group and 41.7% in the A-T-carboplatin group), but reached 85.7% with the addition of pembrolizumab and carboplatin. Among the low TIL group, the pCR rate increased from 26.7% to 61.1% with the addition of carboplatin, but there was no difference in the pCR rate between the carboplatin and pembrolizumab groups (61.1% and 60.9%, respectively). In clinically node-positive patients, the pCR rate significantly increased with pembrolizumab in the high TIL group (40.9% versus 100%, p=0.035). However, in low TIL patients, the addition of carboplatin alone significantly increased the pCR rate to 62.3%, whereas the addition of pembrolizumab did not show the same effect. Conclusions Our real-world data consistently demonstrates an increased pCR rate with the addition of carboplatin and pembrolizumab. Among patients with high TIL, the addition of carboplatin did not result in an elevated pCR rate. However, the addition of pembrolizumab tended to maximize the pCR rate, surpassing 80%. On the other hand, among patients with low TIL, the addition of carboplatin significantly increased the pCR rate, while the addition of pembrolizumab did not have the same effect. Efforts should be made to improve the response to pembrolizumab-containing regimens for patients with low baseline TIL levels. Citation Format: Min Ji Kim, Yoonwon Kook, Seung Ho Baek, Junghyun Kim, Sohyun Moon, Seung Eun Lee, Jee Hung Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong. Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PS16-06.

The Influence of Platinum Additives on the Activity and Stability of Rh-Containing Catalyst for the Conversion of Diesel Fuel into Synthesis Gas

The Influence of Platinum Additives on the Activity and Stability of Rh-Containing Catalyst for the Conversion of Diesel Fuel into Synthesis Gas

Uptake and accumulation mechanisms of hexachloroplatinate(IV) ions in the unicellular alga, Pseudococcomyxa simplex.

Platinum uptake was examined by adding hexachloroplatinate(IV) solution to the unicellular alga Pseudococcomyxa simplex. After the addition of platinum solution ([Pt] = 100mg/kg, pH 3.2-3.2) for a certain time, the cells were quickly frozen and subjected to μ-XRF (X-ray fluorescence) analysis using synchrotron X-rays. The beam size of approximately 1 micrometer allowed visualization of the platinum distribution within a single cell. On the other hand, we examined platinum uptake in enzyme-treated protoplasts and lyophilized cells and found that the platinum uptake concentrations in these samples were higher than in living in-vivo cells. Cell wall and cell metabolism were presumed to interfere with the uptake of hexachloroplatinate(IV) ions. All platinum ions taken up by the cells were reduced to divalent form. The effect of light on platinum addition was also investigated. When platinum was added under light conditions, some samples showed higher platinum accumulation than under shade conditions.

Non-Isothermal Analysis of the Crystallization Kinetics of Amorphous Mg72Zn27Pt1 and Mg72Zn27Ag1 Alloys.

In this study, thin ribbons of amorphous Mg72Zn27Pt1 and Mg72Zn27Ag1 alloys with potential use in biomedicine were analyzed in terms of the crystallization mechanism. Non-isothermal annealing in differential scanning calorimetry (DSC) with five heating rates and X-ray diffraction (XRD) during heating were performed. Characteristic temperatures were determined, and the relative crystalline volume fraction was estimated. The activation energies were calculated using the Kissinger method and the Avrami exponent using the Jeziorny-Avrami model. The addition of platinum and silver shifts the onset of crystallization towards higher temperatures, but Pt has a greater impact. In each case, Eg > Ex > Ep (activation energy of the glass transition, the onset of crystallization, and the peak, respectively), which indicates a greater energy barrier during glass transition than crystallization. The highest activation energy was observed for Mg72Zn27Pt1 due to the difference in the size of the atoms of all alloy components. The crystallization in Mg72Zn27Ag1 occurs faster than in Mg72Zn27Pt1, and the alloy with Pt has higher (temporary) thermal stability. The Avrami exponent (n) values oscillate in the range of 1.7-2.6, which can be interpreted as one- and two-dimensional crystal growth with a constant/decreasing nucleation rate during the process. Moreover, the lower the heating rate, the higher the nucleation rate. The values of n for Mg72Zn27Pt1 indicate a greater number of nuclei and grains than for Mg72Zn27Ag1. The XRD tests indicate the presence of α-Mg and Mg12Zn13 for both Mg72Zn27Pt1 and Mg72Zn27Ag1, but the contribution of the Mg12Zn13 phase is greater for Mg72Zn27Ag1.

Effect of Platinum Addition on Microstructure and Oxidation Behavior of Ni3Al-Base Alloys

Effect of Platinum Addition on Microstructure and Oxidation Behavior of Ni3Al-Base Alloys

Thermokinetic Study of Catalytic Pyrolysis of Medium-Density Fiberboards over Beta-Zeolite-Supported Platinum

Catalytic pyrolysis is an attractive alternative for converting biomass into energy and chemicals, replacing fossil sources. Efficient catalysts can be used to remove compounds containing oxygen during pyrolysis, improving the bio-oil properties and thus being an important route towards sustainability. Catalytic pyrolysis of medium-density fiberboard (MDF) residues over platinum (1%) supported on beta zeolite was carried out using a biomass/catalyst ratio of 1.0/0.2. The catalysts were characterized via Fourier transform infrared spectroscopy, flame atomic absorption spectrometry, X-ray diffraction, nuclear magnetic resonance, temperature-programmed reduction, and temperature-programmed desorption of ammonia. The thermokinetic and thermodynamic parameters were determined using the isoconversional and non-isothermal methods of Friedman, Flynn-Wall-Ozawa (FWO), and Kissinger-Ahakira-Sunose (KAS). The Friedman method was the most adequate to describe the reaction and thermodynamic parameters. The results show that the catalysts promote the reduction in activation energy compared to non-catalytic pyrolysis. Non-impregnated and impregnated catalysts showed different activation energies and thus different reactions. The addition of platinum slightly increased the activation energy due to the promotion of reactions that require more energy, for example, cracking and coke deposition.

Platinum-based chemotherapy in patients with castration-resistant prostate cancer and hepatic metastases.

e17063 Background: Patients with metastatic castration-resistant prostate cancer (mCRPC) and hepatic metastases face a dismal prognosis. In fact, the majority of phase 3 trials show no benefit of novel treatment modalities including Lutetium PSMA radioligand therapy (LuPSMA-RLT) in comparison with standard therapies for the subgroup of visceral metastases. In aggressive variant prostate cancer, the addition of platinum resulted in a clinically relevant improvement of progression free survival (PFS) and overall survival (OS). Whether adding platinum is also beneficial in unselected mCRPC patients with hepatic metastasis is unclear. Methods: We retrospectively analyzed mCRPC patients diagnosed with hepatic metastasis and treated with platinum-based chemotherapy or LuPSMA-RLT in three German centers (Hamburg, Essen, Munich). Patients with pure neuroendocrine prostate cancer were excluded. Survival rates and 95% confidence intervals (CI) were compared using the Kaplan Meier method and the logRank test. Results: A total of 84 mCRPC patients with hepatic metastasis who had received at least one platinum-based therapy and 32 patients treated with LuPSMA-RLT were evaluated. Median age at treatment initiation was 67 and 73 years. Patients had undergone a median of three treatment lines (83% ≥ 1 new hormonal agent (NHA); 87% ≥ 1 taxane based chemotherapy) before initiation of platinum based chemotherapy and a median of 4 treatment lines before LuPSMA-RLT. Median time to initiation of 1st platinum-based chemotherapy after diagnosis of liver metastases was 55 days. In total, 37% received carboplatin/cabazitaxel, 26% cisplatin or carboplatin/ etoposide, 11% carboplatin/docetaxel, and 26% other platinum-based combination therapies. In the platinum-treated group, 52.6% and 27% of the patients did not show progression at 3 and 6 months after treatment initiation as compared to 44.1% and 19.3% of the patients who received LuPSMA-RLT with a median PFS of 3.1 and 2.4 months, respectively. At 6 months 71.3% of the platinum-treated patients and 56.6% of the LuPSMA-RLT were alive. Overall, BRCA1/2 status was available for 53 of the platinum-treated patients, 15% of whom had a pathogenic alteration in either gene. This small subgroup was found to have a similar OS compared to the overall cohort. Conclusions: Platinum-based chemotherapy showed promising activity in mCRPC patients with hepatic metastasis. Given the high unmet medical need, platinum-based combination therapies should be further evaluated prospectively. [Table: see text]

Targeting homologous recombination deficiency in uterine leiomyosarcoma

BackgroundUterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting.MethodsA cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting.ResultsAll 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs.ConclusionsOur work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.

Abstract GS5-01: Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial

Abstract Background: Despite several studies, the impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. We conducted a single-centre randomized phase III trial to evaluate the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in these patients. Methods: Patients with histopathological diagnosis of TNBC without evidence of distant metastases who were planned to be treated with neoadjuvant chemotherapy (NACT) were randomized to experimental or control arms after stratification by menopausal status (premenopausal or perimenopausal, and postmenopausal) and stage [operable breast cancer (OBC, clinical T1-3, N0-1, M0), and locally advanced breast cancer (LABC, cT4 or N2-3, M0)]. NACT in control arm included paclitaxel 100 mg/m2 once per week for 8 weeks followed by doxorubicin (60 mg/m2) or epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) once every 21 days for 4 cycles while in experimental arm carboplatin (area-under-curve 2) was added once per week for 8 weeks with paclitaxel. After NACT patients received standard surgery for primary tumor and axillary lymph nodes (LN) followed by radiotherapy. The primary endpoint was disease-free survival (DFS) and the secondary endpoints were overall survival (OS), pathological complete response (pCR, absence of invasive cancer from breast and LN), and toxicity. Results: Between April 2010 and January 2020, 720 (355 control, 365 experimental) patients with a median age of 46 (25-69) years [&amp;lt; 50 years, 502 (69.7%), premenopausal 418 (58.2%)], were included in the study, of whom 285 (39.6%) had OBC and 435 (60.4%) had LABC, with a median clinical tumor size of 6.0 (1.2- 20.0) cm. At a median follow-up of 67.6 (18.9-142.2) months, in the experimental and control arms, the 5-year DFS were 70.6% (95% CI 65.7-75.5%) and 64.5% (95% CI 59.4-69.6%), respectively (HR 0.79, 95% CI 0.61-1.02, p=0.073), 5-year OS were 74.0 (95% CI 69.3-78.7%) and 66.7% (95% CI 61.6-71.8%), respectively (HR 0.75, 95% CI 0.57-0.98, p=0.034), and pCR were 55.2% (95% CI 49.7-69.5%) and 41.5% (95% CI 36.2-47.0%), respectively (p=0.0004). In subgroup analyses, the benefit of carboplatin was confined to patient’s &amp;lt; 50 years, with significant interaction between treatment and age. In women &amp;lt; 50 years of age, in experimental versus control arms, 5-year DFS and OS were 74.5% vs 62.3% (p=0.003, interaction p=0.003) and 76.8% vs 65.7% (p=0.003, interaction p=0.004), respectively. Addition of carboplatin had a significant beneficial impact on OS after adjusting for baseline clinical tumor size and age in a Cox model (HR 0.75, 95% CI 0.58-0.98, p=0.038). In experimental and control arms, numbers of patients with any grade &amp;gt;/=3 toxicity were 140 (38.5%) and 107/355 (30.14%), respectively, (p=0.02), grade &amp;gt;/=3 neutropenia were 2/364 (0.55%) and 1/355 (0.28%), respectively, grade &amp;gt;/=3 thrombocytopenia were 1/364 (0.27%) and 0 (0%), respectively, and febrile neutropenia were 26/364 (7.14%%) and 18/355 (5.07%), respectively (p=0.25). Conclusions: This study, to our knowledge the largest reported trial of neoadjuvant platinum in TNBC thus far, suggests that addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy results in substantial and clinically meaningful improvement in disease-free and overall survival in young patients with TNBC and should be the standard of care in these patients. Citation Format: Sudeep Gupta, Nita S. Nair, Rohini Hawaldar, Vaibhav Vanmali, Vani Parmar, Seema Gulia, Jaya Ghosh, Shalaka Joshi, Rajiv Sarin, Tabassum Wadasadawala, Tejal Panhale, Sangeeta Desai, Tanuja Shet, Asawari Patil, Garvit Chitkara, Sushmita Rath, Jyoti Bajpai, Meenakshi Thakkur, Rajendra Badwe. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS5-01.

Influence of platinum on ablation behavior of silicone rubber

The influence of platinum on silicone rubber ablation was studied by muffle furnace,X-ray diffraction (XRD) and X-ray photoelectron spectroscopy (XPS). The addition of platinum promoted ceramic formation, causing the silicone compound to burn into a hard ceramic, significantly increasing the residual weight. The XRD showed that the crystallization peak was weakened and the crystal structure was disrupted. The XPS revealed a decrease in the calcium content in the residue.Overall,the addition of platinum allowed the decomposition products of silicone rubber to participate in the ceramic process and form a hard solid.

Effect of platinum addition on the reaction mechanism of the CO2 methanation catalyzed by ZrO2-supported Rh

In this study the effect of platinum on the catalysis during the CO2 methanation on ZrO2-supported Rh samples was evaluated. Zirconium oxide was synthetized by a precipitation method, while the platinum and rhodium were supported by wet impregnation in order to obtain samples with 1%w/w of metallic load. The catalytic tests show that in the presence of the Rh/ZrO2 sample only CH4 and H2O were formed, whereas in the presence of Pt/ZrO2 sample only CO and H2O were produced. Additionally, the data also show that the combination of appropriate amounts of Pt and Rh on ZrO2 increases the CO2 conversion and the methane production significantly in comparison with those observed in the presence of the Rh/ZrO2 catalyst (at 300°C). FTIR spectra collected under reaction conditions revealed that the increase in the catalytic activity in bimetallic samples can be related with the increase in the formation of Rh-CO species (fundamental for methane production), which are promoted possibly by the Pt incorporation to Rh/ZrO2 samples, because the COads formation (on Pt sites) occurs by reverse water gas shift, which is more favorable energetically than the CO2 dissociation on Rh sites.

202 (PB-115) Poster - Pathologic complete response in triple negative breast cancer - A single Portuguese center experience

Background: Triple-negative breast cancer (TNBC) accounts for 15–20% of all invasive breast cancer (BC) and is frequently associated with adverse prognosis. Pathologic complete response (pCR) has been associated with improved survival in early-stage BC. While anthracycline and taxane-based neoadjuvant chemotherapy (NCT) remains the standard of care, addition of platinum seems to increase pCR rate, with no significant difference in survival. Objectives of this study are to review clinical decisions regarding NCT and to evaluate the pCR rate in TNBC patients (pts) in our centre.

Nanocatalytic Interface to Decode the Phytovolatile Language for Latent Crop Diagnosis in Future Farms.

Crop diseases cause the release of volatiles. Here, the use of an SnO2-based chemoresistive sensor for early diagnosis has been attempted. Ionone is one of the signature volatiles released by the enzymatic and nonenzymatic cleavage of carotene at the latent stage of some biotic stresses. To our knowledge, this is the first attempt at sensing volatiles with multiple oxidation sites, i.e., ionone (4 oxidation sites), from the phytovolatile library, to derive stronger signals at minimum concentrations. Further, the sensitivity was enhanced on an interdigitated electrode by the addition of platinum as the dopant for a favorable space charge layer and for surface island formation for reactive interface sites. The mechanistic influence of oxygen vacancy formation was studied through detailed density functional theory (DFT) calculations and reactive oxygen-assisted enhanced binding through X-ray photoelectron spectroscopy (XPS) analysis.